Clinical trial
An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone in the Treatment of Pediatric Patients With Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder
NCT06229210 is registered in ClinicalTrials.gov with Intra-Cellular Therapies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone in the Treatment of Pediatric Patients With Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 25, 2024
- Completion date
- April 28, 2032
- Enrollment
- 300 (estimated)
- Sites
- 65
Conditions
As the registry lists them; a condition with its own page is linked.